PENTIXAPHARM HOLDING N AG Total Liabilities
PENTIXAPHARM HOLDING N AG total liabilities. Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has total liabilities worth €10.04 Million EUR (≈ $11.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of PENTIXAPHARM HOLDING N AG to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PENTIXAPHARM HOLDING N AG (2021–2025)
Total liabilities of PENTIXAPHARM HOLDING N AG from 2021 to 2025. This chart illustrates how PENTIXAPHARM HOLDING N AG's total liabilities have evolved over time, based on quarterly financial data.
PENTIXAPHARM HOLDING N AG Competitors by Total Liabilities
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Corero Network Security plc
LSE:CNS
|
UK | GBX13.32 Million |
|
2CUREX AB SEK-10
F:2QE
|
Germany | €4.55 Million |
|
Pacific Bay Minerals Ltd
V:PBM
|
Canada | CA$688.59K |
|
Identillect Technologies Corp
V:ID
|
Canada | CA$1.75 Million |
|
Alveen
PA:MLALV
|
France | €792.00K |
|
Tlou Energy Ltd
AU:TOU
|
Australia | AU$23.72 Million |
|
Cake Box Holdings PLC
LSE:CBOX
|
UK | GBX36.08 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down PENTIXAPHARM HOLDING N AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is PENTIXAPHARM HOLDING N AG's balance sheet.
Liquidity & Leverage Metrics
PENTIXAPHARM HOLDING N AG Total Liabilities Ratios Explained
PENTIXAPHARM HOLDING N AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PENTIXAPHARM HOLDING N AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual total liabilities of PENTIXAPHARM HOLDING N AG from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €6.79 Million ≈ $7.93 Million |
-62.24% |
| 2024-12-31 | €17.97 Million ≈ $21.01 Million |
-27.87% |
| 2023-12-31 | €24.92 Million ≈ $29.13 Million |
+61.69% |
| 2022-12-31 | €15.41 Million ≈ $18.02 Million |
+1119.15% |
| 2021-12-31 | €1.26 Million ≈ $1.48 Million |
-- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunologic… Read more